

PreveCeutical Medical Inc.

09:29 13 Feb 2019

PreveCeutical Medical appoints Dr Makarand Jawadekar as president

PreveCeutical Medical (CSE:PREV) (OTCQB:PRVCF) is shaking up its management team, with the appointment of its chief scientific officer Dr. Makarand "Mak" Jawadekar as president.

Former president, Stephen Van Deventer will continue to serve as chairman and CEO of PreveCeutical.

READ: PreveCeutical explores partnerships with pharma and biotech companies for co-development of its Sol-Gel nasal delivery system

Jawadekar, who is also a director of PreveCeutical, previously spent 28 years at Pfizer (NYSE:PFE), where he served as director of portfolio management. During his tenure at the pharmaceutical giant, he also worked as a bench scientist for the formulation of the blockbuster drug Zolofit.

"I look forward to Mak's direction as president as we move forward with our plans to secure strategic partnerships to accelerate PreveCeutical's innovative research and development programs to commercialization," said CEO Van Deventer in a statement. "Mak's expertise and high-level associates in the pharmaceutical sector is of extreme value to us in the company's exciting next phase."

Jawadekar also said he is looking forward to his new post.

READ: PreveCeutical says C\$16.25M Crushedit supply deal and Asterion Cannabis licensing deal among 2018 milestones

"I am very pleased to accept the new role of president and I hope to add further value through making selective contributions to the company's product portfolio beyond science and technology," he said in a statement.

Headquartered in Vancouver, PreveCeutical is a health sciences company that develops therapies using natural and organic products. The focus of its research and development programs include non-addictive peptides as a replacement for highly-addictive morphine, fentanyl and oxycodone, its Sol-Gel nose-to-brain delivery system as well as therapies for treating athletes who suffer from concussions.


PreveCeutical shares fell 10% to hit C\$0.045 on Tuesday.

Contact Ellen Kelleher at ellen@proactiveinvestors.com

Price: 0.04

Market Cap: \$19.68 m

1 Year Share Price Graph



Share Information

Code: PREV

Listing: CSE

52 week High Low
0.1 0.01

Sector: Medical technology & services

Website: preveceutical.com

Company Synopsis:

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).